Demand for active pharmaceutical ingredients is increasing steadily, and the trend is expected to persist. This is due to rising prevalence of infectious and chronic diseases and increasing drug production globally.
According to Coherent Market Insights, the global active pharmaceutical ingredients industry size is set to reach US$ 372.4 billion in 2030. Global API demand will likely surge at a CAGR of 6.8% during the assessment period.
Teva Pharmaceutical Industries Ltd, Cipla Limited, Novartis AG, Lupin Limited, Mylan N.V., and Prizer are few leading API manufacturers. Top players are striving to launch new APIs for different indications. They are investing rigorously in research and development to explore more efficient synthesis processes, enhance yields, and lower production costs.
Leading API companies are focusing on complying with stringent regulations set by various regulatory agencies. They are adopted strategies like partnerships, collaborations, acquisitions, and mergers to expand their global footprint.
In January 2024, Teva Pharmaceutical Industries announced its intention to divest its TAPI or active pharmaceutical ingredient business. This development will allow Teva to significantly improve its potential revenue streams and focus on growth and innovation.
In January 2025, Lupin Limited launched Minzoya TM in the United States. It is a generic equivalent of Balcoltra indicated for use by females of reproductive potential to prevent pregnancy.
In August 2024, Novartis received US FDA approval for Fabhalta (iptacopan). It is the first and the only complement inhibitor for reducing proteinuria in adults with primary IgA nephropathy.
Key Factors Propelling Active Pharmaceutical Ingredients Industry Growth
The future of active pharmaceutical ingredients industry looks bright and exciting. This is due to rising incidence of various chronic diseases, increasing demand for generic drugs, and innovation in API manufacturing.
The world is witnessing a spike in cases of diabetes, cancer, autoimmune diseases, and cardiovascular disorders. This is expected to propel demand for effective medications, leading to increasing API production.
Active pharmaceutical ingredients are the core components of drugs. These biologically active ingredients are responsible for producing the desired therapeutic effects of the medication. Demand for APIs is rising in tandem with growing prevalence of various diseases.
Growing popularity of biopharmaceuticals is also boosting the APIs industry. There is a growing interest in biologics and biosimilars, creating a high need for specialized APIs.
Innovations like 3D printing are revolutionizing API production. They enable precise dosing and creation of complex drug formulation. Increasing adoption of these technologies is expected to positively impact the target industry during the forecast period.
Regional Insights
North America is set to dominate the global active pharmaceutical ingredients (APIs) industry during the assessment period. This is mainly due to rising cases of chronic diseases, favorable government support, and growing popularity of biopharmaceuticals.
There is a rising demand for biological APIs in North America. This is due to high adoption of biological drugs for treating chronic diseases like cancer. Strong presence of leading API manufacturers, increasing investments in R&D, and continuous new drug approvals also support industry expansion in the region.
